| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Polymorphism, Single Nucleotide | 24 | 2019 | 3607 | 4.59 | Why? |
| Genetic Predisposition to Disease | 31 | 2021 | 4027 | 3.91 | Why? |
| Arthritis, Juvenile | 5 | 2018 | 191 | 2.87 | Why? |
| Toll-Like Receptors | 6 | 2021 | 365 | 2.72 | Why? |
| Stomatitis, Aphthous | 4 | 2018 | 43 | 2.69 | Why? |
| Immunotherapy | 11 | 2021 | 2421 | 2.25 | Why? |
| Immunologic Deficiency Syndromes | 10 | 2018 | 368 | 2.23 | Why? |
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 3 | 2019 | 7 | 2.20 | Why? |
| STAT4 Transcription Factor | 3 | 2017 | 16 | 2.01 | Why? |
| Autism Spectrum Disorder | 5 | 2019 | 587 | 2.01 | Why? |
| Gene Frequency | 17 | 2018 | 1210 | 1.93 | Why? |
| Iran | 37 | 2021 | 5467 | 1.91 | Why? |
| Interleukin-2 | 4 | 2018 | 443 | 1.91 | Why? |
| Interleukin-4 | 3 | 2018 | 367 | 1.83 | Why? |
| Genetic Association Studies | 10 | 2018 | 559 | 1.76 | Why? |
| Genotype | 21 | 2019 | 4697 | 1.60 | Why? |
| Methyl-CpG-Binding Protein 2 | 2 | 2017 | 12 | 1.47 | Why? |
| Autoimmunity | 10 | 2021 | 841 | 1.46 | Why? |
| Central Nervous System Viral Diseases | 2 | 2020 | 117 | 1.45 | Why? |
| Lymphoma, Non-Hodgkin | 3 | 2018 | 403 | 1.42 | Why? |
| Alleles | 14 | 2018 | 1557 | 1.39 | Why? |
| Tumor Microenvironment | 3 | 2018 | 264 | 1.38 | Why? |
| Omalizumab | 2 | 2021 | 158 | 1.37 | Why? |
| Neutropenia | 5 | 2018 | 388 | 1.34 | Why? |
| Agammaglobulinemia | 4 | 2018 | 213 | 1.33 | Why? |
| Haplotypes | 10 | 2018 | 853 | 1.33 | Why? |
| Transforming Growth Factor beta | 3 | 2018 | 363 | 1.32 | Why? |
| Interleukin-10 | 4 | 2018 | 1409 | 1.31 | Why? |
| Cytokines | 17 | 2021 | 15010 | 1.30 | Why? |
| Common Variable Immunodeficiency | 6 | 2018 | 195 | 1.30 | Why? |
| Amyloid beta-Peptides | 2 | 2018 | 185 | 1.28 | Why? |
| Antibodies, Monoclonal | 9 | 2020 | 8041 | 1.16 | Why? |
| Humans | 216 | 2021 | 930598 | 1.15 | Why? |
| Interleukin-17 | 3 | 2019 | 602 | 1.15 | Why? |
| T-Lymphocytes, Regulatory | 5 | 2018 | 698 | 1.09 | Why? |
| Colitis, Ulcerative | 3 | 2019 | 1037 | 1.08 | Why? |
| Selenium | 2 | 2021 | 412 | 1.06 | Why? |
| Hepatitis, Autoimmune | 2 | 2018 | 254 | 1.06 | Why? |
| Pediatricians | 2 | 2020 | 401 | 1.04 | Why? |
| Signal Transduction | 12 | 2021 | 7207 | 1.01 | Why? |
| Shock | 2 | 2021 | 1868 | 1.00 | Why? |
| Adaptor Proteins, Signal Transducing | 6 | 2018 | 502 | 0.99 | Why? |
| Interferon-gamma | 3 | 2017 | 2711 | 0.99 | Why? |
| Severe Combined Immunodeficiency | 2 | 2021 | 107 | 0.96 | Why? |
| Molecular Targeted Therapy | 4 | 2020 | 1579 | 0.95 | Why? |
| Case-Control Studies | 23 | 2019 | 17671 | 0.90 | Why? |
| Severe Acute Respiratory Syndrome | 7 | 2021 | 12361 | 0.90 | Why? |
| Interleukin-4 Receptor alpha Subunit | 2 | 2018 | 46 | 0.89 | Why? |
| Models, Genetic | 2 | 2020 | 434 | 0.84 | Why? |
| Linkage Disequilibrium | 2 | 2017 | 191 | 0.84 | Why? |
| Toll-Like Receptor 9 | 2 | 2018 | 72 | 0.84 | Why? |
| Immune System | 2 | 2020 | 1479 | 0.83 | Why? |
| Antibodies, Anti-Idiotypic | 1 | 2020 | 93 | 0.82 | Why? |
| Brain Infarction | 1 | 2021 | 129 | 0.80 | Why? |
| Coronavirus Infections | 31 | 2021 | 253789 | 0.80 | Why? |
| Campylobacter jejuni | 1 | 2019 | 27 | 0.79 | Why? |
| Interleukin-6 | 5 | 2020 | 7522 | 0.78 | Why? |
| Pandemics | 49 | 2021 | 389249 | 0.78 | Why? |
| Betacoronavirus | 26 | 2021 | 204454 | 0.78 | Why? |
| Cancer Vaccines | 1 | 2021 | 136 | 0.77 | Why? |
| Radioimmunotherapy | 1 | 2018 | 5 | 0.75 | Why? |
| Retroviridae | 1 | 2018 | 49 | 0.75 | Why? |
| Genes, Dominant | 1 | 2018 | 18 | 0.74 | Why? |
| Consolidation Chemotherapy | 1 | 2018 | 41 | 0.74 | Why? |
| Genetic Therapy | 2 | 2020 | 409 | 0.74 | Why? |
| Neuroblastoma | 1 | 2019 | 91 | 0.73 | Why? |
| Hospitalists | 1 | 2020 | 109 | 0.73 | Why? |
| Chromosome Inversion | 1 | 2017 | 5 | 0.73 | Why? |
| E-Selectin | 1 | 2018 | 55 | 0.73 | Why? |
| Anthocyanins | 1 | 2018 | 51 | 0.73 | Why? |
| Crohn Disease | 2 | 2018 | 959 | 0.73 | Why? |
| Eosinophilic Esophagitis | 1 | 2018 | 35 | 0.73 | Why? |
| Disorders of Sex Development | 1 | 2017 | 8 | 0.72 | Why? |
| Pneumonia, Viral | 27 | 2020 | 243684 | 0.72 | Why? |
| Promoter Regions, Genetic | 3 | 2018 | 823 | 0.72 | Why? |
| Intervertebral Disc Degeneration | 1 | 2018 | 31 | 0.72 | Why? |
| Alzheimer Disease | 2 | 2018 | 1020 | 0.71 | Why? |
| Peer Review | 1 | 2020 | 204 | 0.71 | Why? |
| Frontal Lobe | 1 | 2019 | 191 | 0.71 | Why? |
| Vascular Cell Adhesion Molecule-1 | 1 | 2018 | 121 | 0.70 | Why? |
| Spinal Nerves | 1 | 2017 | 18 | 0.70 | Why? |
| Synaptic Transmission | 1 | 2017 | 46 | 0.70 | Why? |
| Neoplasm Metastasis | 2 | 2018 | 682 | 0.69 | Why? |
| Friedreich Ataxia | 1 | 2017 | 6 | 0.69 | Why? |
| Interleukin-2 Receptor alpha Subunit | 2 | 2018 | 234 | 0.69 | Why? |
| Nerve Regeneration | 1 | 2017 | 26 | 0.69 | Why? |
| Chromosomes, Human, Pair 9 | 1 | 2017 | 196 | 0.69 | Why? |
| Gene Expression Regulation | 4 | 2018 | 4020 | 0.69 | Why? |
| Apraxias | 1 | 2017 | 11 | 0.68 | Why? |
| p38 Mitogen-Activated Protein Kinases | 1 | 2018 | 230 | 0.68 | Why? |
| Adrenal Insufficiency | 1 | 2020 | 190 | 0.68 | Why? |
| rac1 GTP-Binding Protein | 1 | 2017 | 32 | 0.68 | Why? |
| Medical Errors | 1 | 2020 | 201 | 0.68 | Why? |
| Cachexia | 1 | 2018 | 75 | 0.68 | Why? |
| Molecular Mimicry | 1 | 2019 | 190 | 0.68 | Why? |
| Immune Tolerance | 3 | 2018 | 608 | 0.67 | Why? |
| Neoplasms | 8 | 2021 | 17251 | 0.67 | Why? |
| Neurotransmitter Agents | 1 | 2017 | 57 | 0.67 | Why? |
| Tumor Necrosis Factor-alpha | 4 | 2020 | 2483 | 0.67 | Why? |
| Interferon Regulatory Factors | 1 | 2018 | 141 | 0.67 | Why? |
| tau Proteins | 1 | 2018 | 162 | 0.66 | Why? |
| Th17 Cells | 3 | 2019 | 657 | 0.66 | Why? |
| Mucocutaneous Lymph Node Syndrome | 2 | 2021 | 1645 | 0.66 | Why? |
| Osteopontin | 1 | 2018 | 96 | 0.66 | Why? |
| Seizures, Febrile | 1 | 2017 | 59 | 0.66 | Why? |
| Receptors, CXCR4 | 1 | 2017 | 83 | 0.66 | Why? |
| Gene Editing | 1 | 2020 | 330 | 0.65 | Why? |
| Colonic Neoplasms | 1 | 2021 | 295 | 0.65 | Why? |
| Intercellular Adhesion Molecule-1 | 1 | 2018 | 189 | 0.65 | Why? |
| Forkhead Transcription Factors | 1 | 2018 | 231 | 0.65 | Why? |
| Warts | 1 | 2017 | 59 | 0.64 | Why? |
| Mitogen-Activated Protein Kinases | 1 | 2017 | 126 | 0.64 | Why? |
| Serine Proteinase Inhibitors | 1 | 2020 | 341 | 0.64 | Why? |
| Lab-On-A-Chip Devices | 1 | 2020 | 411 | 0.64 | Why? |
| International Cooperation | 2 | 2020 | 3436 | 0.63 | Why? |
| Cell- and Tissue-Based Therapy | 1 | 2021 | 422 | 0.63 | Why? |
| Autophagy | 2 | 2021 | 960 | 0.63 | Why? |
| Brain-Derived Neurotrophic Factor | 1 | 2017 | 133 | 0.63 | Why? |
| Antibodies | 2 | 2020 | 846 | 0.63 | Why? |
| Child | 39 | 2021 | 70012 | 0.62 | Why? |
| Autoimmune Diseases | 5 | 2021 | 1996 | 0.62 | Why? |
| Immunoglobulins | 2 | 2020 | 811 | 0.62 | Why? |
| Lupus Erythematosus, Systemic | 2 | 2017 | 1380 | 0.61 | Why? |
| Nervous System Diseases | 4 | 2021 | 4092 | 0.61 | Why? |
| Genetic Diseases, X-Linked | 1 | 2018 | 237 | 0.61 | Why? |
| Glioma | 1 | 2018 | 189 | 0.60 | Why? |
| Food | 1 | 2018 | 316 | 0.60 | Why? |
| Neuritis | 1 | 2017 | 109 | 0.59 | Why? |
| Animals | 33 | 2021 | 78931 | 0.59 | Why? |
| Metals, Heavy | 1 | 2017 | 147 | 0.59 | Why? |
| Th1 Cells | 2 | 2018 | 1228 | 0.58 | Why? |
| Toll-Like Receptor 4 | 5 | 2018 | 390 | 0.58 | Why? |
| Antiviral Agents | 13 | 2021 | 41703 | 0.58 | Why? |
| Anti-Asthmatic Agents | 2 | 2017 | 427 | 0.57 | Why? |
| Myeloid-Derived Suppressor Cells | 1 | 2018 | 316 | 0.57 | Why? |
| Amyloidosis | 1 | 2017 | 178 | 0.57 | Why? |
| Interleukin-1 | 1 | 2018 | 438 | 0.56 | Why? |
| Leukocytes, Mononuclear | 4 | 2018 | 2115 | 0.56 | Why? |
| Immunosuppressive Agents | 4 | 2020 | 6331 | 0.56 | Why? |
| Diabetes Mellitus, Type 1 | 3 | 2018 | 1969 | 0.55 | Why? |
| Endometriosis | 1 | 2016 | 130 | 0.55 | Why? |
| Skin Diseases, Viral | 1 | 2020 | 436 | 0.54 | Why? |
| Infertility, Female | 1 | 2016 | 150 | 0.54 | Why? |
| Trace Elements | 1 | 2017 | 284 | 0.53 | Why? |
| Adenocarcinoma | 1 | 2021 | 651 | 0.53 | Why? |
| Infliximab | 1 | 2018 | 502 | 0.53 | Why? |
| Disease Eradication | 1 | 2020 | 581 | 0.53 | Why? |
| Medicine | 1 | 2021 | 485 | 0.53 | Why? |
| Inflammatory Bowel Diseases | 4 | 2018 | 3209 | 0.52 | Why? |
| Nanotechnology | 1 | 2020 | 821 | 0.52 | Why? |
| Pathology, Molecular | 1 | 2017 | 343 | 0.52 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 9335 | 0.52 | Why? |
| Virus Internalization | 4 | 2020 | 7921 | 0.52 | Why? |
| Phytochemicals | 1 | 2020 | 678 | 0.51 | Why? |
| Radiopharmaceuticals | 1 | 2018 | 763 | 0.51 | Why? |
| Developed Countries | 1 | 2017 | 500 | 0.50 | Why? |
| Furin | 1 | 2020 | 1054 | 0.50 | Why? |
| Positron-Emission Tomography | 1 | 2018 | 802 | 0.50 | Why? |
| Micronutrients | 1 | 2017 | 310 | 0.50 | Why? |
| Mesenchymal Stem Cell Transplantation | 3 | 2021 | 1322 | 0.49 | Why? |
| Geography | 1 | 2019 | 1801 | 0.49 | Why? |
| Zinc | 2 | 2017 | 817 | 0.49 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2017 | 724 | 0.49 | Why? |
| Spinal Cord Injuries | 1 | 2017 | 270 | 0.49 | Why? |
| Male | 71 | 2021 | 367725 | 0.48 | Why? |
| Amyotrophic Lateral Sclerosis | 1 | 2018 | 398 | 0.48 | Why? |
| Biomarkers | 9 | 2021 | 23361 | 0.47 | Why? |
| Down Syndrome | 1 | 2017 | 397 | 0.47 | Why? |
| Mutation, Missense | 1 | 2018 | 863 | 0.47 | Why? |
| Immunity | 2 | 2020 | 2651 | 0.46 | Why? |
| DNA | 2 | 2017 | 778 | 0.46 | Why? |
| Calcium | 1 | 2017 | 708 | 0.46 | Why? |
| Physical Therapy Modalities | 1 | 2020 | 1090 | 0.45 | Why? |
| Meningitis, Bacterial | 1 | 2013 | 111 | 0.45 | Why? |
| Phenotype | 12 | 2019 | 4037 | 0.45 | Why? |
| Interferons | 2 | 2021 | 2885 | 0.45 | Why? |
| Tuberculosis, Meningeal | 1 | 2013 | 100 | 0.45 | Why? |
| Antineoplastic Agents, Immunological | 1 | 2018 | 830 | 0.44 | Why? |
| Respiratory Syncytial Virus Infections | 1 | 2021 | 1234 | 0.44 | Why? |
| Lung Injury | 1 | 2020 | 919 | 0.44 | Why? |
| CRISPR-Cas Systems | 1 | 2020 | 1397 | 0.44 | Why? |
| Brain Neoplasms | 1 | 2018 | 669 | 0.44 | Why? |
| Cranial Nerve Diseases | 1 | 2013 | 148 | 0.44 | Why? |
| Geriatrics | 1 | 2021 | 947 | 0.43 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2018 | 1153 | 0.43 | Why? |
| Enzyme Inhibitors | 2 | 2018 | 1881 | 0.43 | Why? |
| Celiac Disease | 1 | 2017 | 471 | 0.42 | Why? |
| Eosinophils | 1 | 2017 | 848 | 0.42 | Why? |
| Interferon Type I | 2 | 2021 | 2789 | 0.42 | Why? |
| Pancreatic Neoplasms | 1 | 2018 | 609 | 0.42 | Why? |
| Histiocytosis, Langerhans-Cell | 1 | 2010 | 46 | 0.42 | Why? |
| Female | 66 | 2021 | 380317 | 0.42 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 3 | 2021 | 8843 | 0.42 | Why? |
| Immunity, Innate | 8 | 2021 | 6570 | 0.42 | Why? |
| Quarantine | 4 | 2021 | 18418 | 0.42 | Why? |
| Choledochal Cyst | 1 | 2009 | 3 | 0.41 | Why? |
| Receptors, Virus | 4 | 2020 | 5659 | 0.40 | Why? |
| Hepacivirus | 1 | 2019 | 1509 | 0.40 | Why? |
| Lipopolysaccharides | 3 | 2019 | 848 | 0.40 | Why? |
| Macrophages | 2 | 2021 | 2784 | 0.39 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 1573 | 0.39 | Why? |
| General Practitioners | 1 | 2017 | 568 | 0.39 | Why? |
| Drug Discovery | 2 | 2020 | 3092 | 0.38 | Why? |
| Endothelium, Vascular | 1 | 2020 | 1751 | 0.38 | Why? |
| Ataxia Telangiectasia | 2 | 2019 | 12 | 0.38 | Why? |
| Gangliosides | 2 | 2019 | 86 | 0.38 | Why? |
| Peptidyl-Dipeptidase A | 5 | 2021 | 9659 | 0.37 | Why? |
| Mutation | 14 | 2021 | 12376 | 0.37 | Why? |
| Clinical Trials as Topic | 4 | 2021 | 7330 | 0.37 | Why? |
| Hexuronic Acids | 2 | 2018 | 11 | 0.37 | Why? |
| Th1-Th2 Balance | 2 | 2018 | 19 | 0.37 | Why? |
| Inflammation | 7 | 2021 | 13255 | 0.36 | Why? |
| Toll-Like Receptor 2 | 3 | 2018 | 198 | 0.36 | Why? |
| Delivery of Health Care, Integrated | 1 | 2020 | 1549 | 0.36 | Why? |
| Heart Failure | 2 | 2021 | 6638 | 0.36 | Why? |
| T-Lymphocytes | 5 | 2021 | 6670 | 0.36 | Why? |
| Thrombophilia | 1 | 2020 | 1935 | 0.36 | Why? |
| Civil Defense | 1 | 2020 | 1687 | 0.36 | Why? |
| Asthma | 2 | 2017 | 4383 | 0.35 | Why? |
| Immunoglobulin E | 3 | 2021 | 557 | 0.35 | Why? |
| Lymphopenia | 1 | 2020 | 2669 | 0.35 | Why? |
| Hepatitis C | 1 | 2019 | 1514 | 0.35 | Why? |
| Drug Design | 2 | 2017 | 2627 | 0.35 | Why? |
| Cognitive Dysfunction | 1 | 2019 | 1389 | 0.34 | Why? |
| Vitamin D | 2 | 2020 | 2904 | 0.34 | Why? |
| Pregnant Women | 1 | 2021 | 2535 | 0.34 | Why? |
| Olfactory Mucosa | 2 | 2020 | 372 | 0.34 | Why? |
| Stroke | 2 | 2021 | 8839 | 0.33 | Why? |
| Research | 1 | 2020 | 2115 | 0.33 | Why? |
| Age of Onset | 3 | 2018 | 557 | 0.33 | Why? |
| Induction Chemotherapy | 2 | 2018 | 149 | 0.33 | Why? |
| Cardiovascular Diseases | 3 | 2020 | 11497 | 0.33 | Why? |
| Vitamin D Deficiency | 1 | 2020 | 1782 | 0.32 | Why? |
| Heterozygote | 2 | 2018 | 249 | 0.32 | Why? |
| Hypersensitivity | 1 | 2017 | 1137 | 0.32 | Why? |
| Carcinogenesis | 2 | 2018 | 236 | 0.32 | Why? |
| Adolescent | 31 | 2021 | 86841 | 0.31 | Why? |
| Adrenal Cortex Hormones | 2 | 2020 | 6537 | 0.30 | Why? |
| Gene Expression | 4 | 2021 | 3332 | 0.30 | Why? |
| Prostatic Neoplasms | 1 | 2018 | 1637 | 0.30 | Why? |
| Diet | 1 | 2018 | 2052 | 0.30 | Why? |
| HIV-1 | 2 | 2018 | 3365 | 0.30 | Why? |
| Guillain-Barre Syndrome | 1 | 2019 | 1495 | 0.30 | Why? |
| Hypoxia | 1 | 2020 | 3626 | 0.30 | Why? |
| Communicable Diseases | 1 | 2021 | 2148 | 0.30 | Why? |
| Hemorrhagic Fever, Ebola | 1 | 2017 | 1475 | 0.30 | Why? |
| Protein Binding | 3 | 2020 | 11430 | 0.29 | Why? |
| Health Services Needs and Demand | 1 | 2020 | 3419 | 0.29 | Why? |
| Multiple Sclerosis | 2 | 2018 | 2600 | 0.29 | Why? |
| Blood Glucose | 2 | 2018 | 3642 | 0.29 | Why? |
| Emergencies | 1 | 2020 | 4095 | 0.28 | Why? |
| Drug Repositioning | 2 | 2020 | 5683 | 0.28 | Why? |
| Parkinson Disease | 1 | 2017 | 1414 | 0.28 | Why? |
| MicroRNAs | 1 | 2018 | 1787 | 0.28 | Why? |
| RNA, Viral | 4 | 2021 | 32276 | 0.28 | Why? |
| DNA Methylation | 2 | 2021 | 688 | 0.28 | Why? |
| Candidiasis, Chronic Mucocutaneous | 2 | 2017 | 17 | 0.28 | Why? |
| Occupational Diseases | 1 | 2020 | 2787 | 0.28 | Why? |
| Serine Endopeptidases | 1 | 2020 | 4606 | 0.28 | Why? |
| Immunotherapy, Adoptive | 2 | 2021 | 524 | 0.27 | Why? |
| Psoriasis | 1 | 2018 | 1739 | 0.27 | Why? |
| Adult | 40 | 2021 | 244371 | 0.27 | Why? |
| Spike Glycoprotein, Coronavirus | 10 | 2021 | 37182 | 0.27 | Why? |
| Immunomodulation | 3 | 2021 | 1472 | 0.27 | Why? |
| Survival Analysis | 4 | 2021 | 7592 | 0.26 | Why? |
| Evidence-Based Medicine | 1 | 2017 | 3228 | 0.26 | Why? |
| Systemic Inflammatory Response Syndrome | 2 | 2021 | 6653 | 0.26 | Why? |
| Immunologic Factors | 4 | 2021 | 4206 | 0.26 | Why? |
| Infant | 14 | 2021 | 30274 | 0.26 | Why? |
| Anti-Inflammatory Agents | 2 | 2020 | 6153 | 0.26 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2021 | 5164 | 0.26 | Why? |
| Adaptive Immunity | 3 | 2021 | 2585 | 0.25 | Why? |
| Treatment Outcome | 11 | 2021 | 51732 | 0.25 | Why? |
| Infant, Newborn | 7 | 2021 | 23105 | 0.25 | Why? |
| Child, Preschool | 17 | 2021 | 36283 | 0.24 | Why? |
| Polymerase Chain Reaction | 4 | 2018 | 6740 | 0.24 | Why? |
| Kidney | 1 | 2017 | 3648 | 0.24 | Why? |
| Esterases | 1 | 2021 | 15 | 0.24 | Why? |
| Healthcare Disparities | 1 | 2020 | 3893 | 0.24 | Why? |
| Olfaction Disorders | 1 | 2020 | 3704 | 0.24 | Why? |
| Job Syndrome | 2 | 2018 | 15 | 0.23 | Why? |
| Genetic Testing | 4 | 2019 | 395 | 0.23 | Why? |
| Ataxia Telangiectasia Mutated Proteins | 2 | 2019 | 48 | 0.23 | Why? |
| Biological Variation, Individual | 1 | 2021 | 66 | 0.22 | Why? |
| Developing Countries | 1 | 2017 | 4283 | 0.22 | Why? |
| Immunoglobulins, Intravenous | 3 | 2020 | 2705 | 0.22 | Why? |
| Genes, X-Linked | 1 | 2020 | 12 | 0.22 | Why? |
| Cytokine Receptor gp130 | 1 | 2020 | 24 | 0.22 | Why? |
| Homozygote | 3 | 2018 | 230 | 0.22 | Why? |
| Lung | 2 | 2020 | 31049 | 0.22 | Why? |
| Ethmoid Bone | 1 | 2020 | 34 | 0.22 | Why? |
| Risk Assessment | 4 | 2021 | 25439 | 0.21 | Why? |
| Hemagglutinins | 1 | 2021 | 143 | 0.21 | Why? |
| Ear Auricle | 1 | 2020 | 62 | 0.21 | Why? |
| Fatal Outcome | 2 | 2021 | 3438 | 0.21 | Why? |
| Age Factors | 6 | 2020 | 21039 | 0.21 | Why? |
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 130 | 0.21 | Why? |
| Health Policy | 2 | 2021 | 6242 | 0.21 | Why? |
| Mannose-Binding Lectin | 1 | 2021 | 131 | 0.21 | Why? |
| Socialization | 1 | 2021 | 91 | 0.21 | Why? |
| Blood Viscosity | 1 | 2020 | 71 | 0.21 | Why? |
| Epidemics | 1 | 2021 | 6407 | 0.21 | Why? |
| Thalamus | 1 | 2020 | 75 | 0.21 | Why? |
| Olfactory Receptor Neurons | 1 | 2020 | 110 | 0.21 | Why? |
| Interdisciplinary Studies | 1 | 2020 | 95 | 0.20 | Why? |
| Genes, Recessive | 4 | 2018 | 35 | 0.20 | Why? |
| N-Myc Proto-Oncogene Protein | 1 | 2019 | 6 | 0.20 | Why? |
| Hyper-IgM Immunodeficiency Syndrome | 1 | 2019 | 5 | 0.20 | Why? |
| Time-to-Treatment | 1 | 2017 | 5883 | 0.20 | Why? |
| Radiation Tolerance | 1 | 2019 | 25 | 0.20 | Why? |
| Combined Modality Therapy | 3 | 2018 | 3395 | 0.20 | Why? |
| Biomedical Engineering | 1 | 2020 | 91 | 0.20 | Why? |
| Critical Illness | 2 | 2020 | 17281 | 0.20 | Why? |
| Rituximab | 2 | 2018 | 1096 | 0.20 | Why? |
| Hypothalamo-Hypophyseal System | 1 | 2021 | 187 | 0.20 | Why? |
| Amniotic Fluid | 1 | 2021 | 249 | 0.20 | Why? |
| Biomedical Research | 1 | 2020 | 5270 | 0.20 | Why? |
| STAT3 Transcription Factor | 2 | 2018 | 268 | 0.19 | Why? |
| Isoantigens | 1 | 2018 | 21 | 0.19 | Why? |
| Brain Stem | 1 | 2020 | 131 | 0.19 | Why? |
| Glutamate Carboxypeptidase II | 1 | 2018 | 24 | 0.19 | Why? |
| Campylobacter Infections | 1 | 2019 | 37 | 0.19 | Why? |
| Pregnancy Trimester, Third | 1 | 2021 | 445 | 0.19 | Why? |
| Regenerative Medicine | 1 | 2021 | 161 | 0.19 | Why? |
| RNA, Guide | 1 | 2020 | 269 | 0.19 | Why? |
| Siblings | 1 | 2020 | 226 | 0.19 | Why? |
| Cystic Fibrosis | 1 | 2009 | 1104 | 0.19 | Why? |
| Gene Rearrangement, T-Lymphocyte | 1 | 2018 | 2 | 0.19 | Why? |
| Hypertension | 1 | 2021 | 8895 | 0.19 | Why? |
| Social Media | 1 | 2021 | 5798 | 0.19 | Why? |
| B-Lymphocytes | 5 | 2018 | 4418 | 0.19 | Why? |
| Threonine | 1 | 2018 | 11 | 0.19 | Why? |
| Health Impact Assessment | 1 | 2020 | 181 | 0.19 | Why? |
| Autoantibodies | 2 | 2021 | 2094 | 0.19 | Why? |
| Plaque, Amyloid | 1 | 2018 | 33 | 0.18 | Why? |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2018 | 526 | 0.18 | Why? |
| Inhibitor of Apoptosis Proteins | 1 | 2017 | 21 | 0.18 | Why? |
| Anus, Imperforate | 1 | 2017 | 1 | 0.18 | Why? |
| Memory | 1 | 2019 | 137 | 0.18 | Why? |
| Mental Disorders | 2 | 2018 | 6742 | 0.18 | Why? |
| Interleukin-5 | 1 | 2018 | 138 | 0.18 | Why? |
| Karyotyping | 1 | 2017 | 52 | 0.18 | Why? |
| Gray Matter | 1 | 2019 | 150 | 0.18 | Why? |
| Nogo Receptors | 1 | 2017 | 2 | 0.18 | Why? |
| Genetic Heterogeneity | 1 | 2018 | 77 | 0.18 | Why? |
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2017 | 15 | 0.18 | Why? |
| Cations, Monovalent | 1 | 2017 | 4 | 0.18 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.18 | Why? |
| Conserved Sequence | 1 | 2020 | 751 | 0.18 | Why? |
| Apoptosis | 3 | 2017 | 2335 | 0.18 | Why? |
| Transforming Growth Factor beta2 | 1 | 2017 | 13 | 0.18 | Why? |
| Poliovirus Vaccines | 1 | 2018 | 85 | 0.18 | Why? |
| Cations, Divalent | 1 | 2017 | 25 | 0.18 | Why? |
| Kallikreins | 1 | 2018 | 158 | 0.17 | Why? |
| Transduction, Genetic | 1 | 2018 | 273 | 0.17 | Why? |
| Risk | 3 | 2020 | 5288 | 0.17 | Why? |
| CRISPR-Associated Proteins | 1 | 2020 | 258 | 0.17 | Why? |
| Receptor for Advanced Glycation End Products | 1 | 2018 | 100 | 0.17 | Why? |
| CD27 Ligand | 1 | 2016 | 17 | 0.17 | Why? |
| Vaccines | 1 | 2017 | 3692 | 0.17 | Why? |
| Maintenance Chemotherapy | 1 | 2018 | 133 | 0.17 | Why? |
| Immunoconjugates | 1 | 2017 | 90 | 0.17 | Why? |
| Antigens, Surface | 1 | 2018 | 181 | 0.17 | Why? |
| Polymorphism, Restriction Fragment Length | 1 | 2017 | 116 | 0.17 | Why? |
| Ectodermal Dysplasia | 1 | 2017 | 39 | 0.17 | Why? |
| Industry | 1 | 2021 | 347 | 0.17 | Why? |
| Stress, Psychological | 1 | 2021 | 10231 | 0.17 | Why? |
| Prostate-Specific Antigen | 1 | 2018 | 213 | 0.17 | Why? |
| Toll-Like Receptor 7 | 1 | 2021 | 402 | 0.17 | Why? |
| Islets of Langerhans Transplantation | 1 | 2017 | 41 | 0.17 | Why? |
| Poliovirus | 1 | 2018 | 109 | 0.17 | Why? |
| Complement System Proteins | 1 | 2020 | 380 | 0.16 | Why? |
| Receptors, KIR | 1 | 2018 | 167 | 0.16 | Why? |
| Mice, Knockout | 2 | 2020 | 1815 | 0.16 | Why? |
| Respiratory Syncytial Viruses | 1 | 2021 | 612 | 0.16 | Why? |
| Mice | 5 | 2020 | 21357 | 0.16 | Why? |
| Publication Bias | 1 | 2018 | 241 | 0.16 | Why? |
| Intensive Care Units | 2 | 2020 | 29594 | 0.16 | Why? |
| Serologic Tests | 2 | 2021 | 4359 | 0.16 | Why? |
| Growth Disorders | 1 | 2017 | 91 | 0.16 | Why? |
| Codon | 1 | 2017 | 287 | 0.16 | Why? |
| Ethics, Research | 1 | 2020 | 328 | 0.16 | Why? |
| T-Lymphocytes, Cytotoxic | 1 | 2020 | 552 | 0.16 | Why? |
| Oligodeoxyribonucleotides | 1 | 2017 | 206 | 0.16 | Why? |
| Causality | 1 | 2020 | 857 | 0.16 | Why? |
| Injury Severity Score | 1 | 2017 | 287 | 0.16 | Why? |
| Acute Disease | 3 | 2020 | 6029 | 0.15 | Why? |
| DNA Repair | 2 | 2017 | 114 | 0.15 | Why? |
| Influenza, Human | 1 | 2021 | 10779 | 0.15 | Why? |
| Oseltamivir | 1 | 2020 | 583 | 0.15 | Why? |
| Blood-Brain Barrier | 1 | 2020 | 531 | 0.15 | Why? |
| Virus Latency | 1 | 2018 | 251 | 0.15 | Why? |
| Confidence Intervals | 1 | 2018 | 744 | 0.15 | Why? |
| Nanomedicine | 1 | 2020 | 329 | 0.15 | Why? |
| Proline | 1 | 2018 | 345 | 0.15 | Why? |
| White Matter | 1 | 2019 | 369 | 0.15 | Why? |
| Hematopoietic Stem Cells | 1 | 2018 | 321 | 0.15 | Why? |
| Transcription Factors | 2 | 2018 | 784 | 0.15 | Why? |
| Hair | 1 | 2017 | 175 | 0.15 | Why? |
| Reference Values | 1 | 2018 | 795 | 0.15 | Why? |
| History, 21st Century | 2 | 2020 | 1849 | 0.15 | Why? |
| Cell Adhesion Molecules | 1 | 2018 | 472 | 0.15 | Why? |
| Consanguinity | 4 | 2018 | 50 | 0.15 | Why? |
| Bias | 1 | 2021 | 1109 | 0.15 | Why? |
| Viral Tropism | 2 | 2020 | 1329 | 0.14 | Why? |
| STAT1 Transcription Factor | 1 | 2017 | 313 | 0.14 | Why? |
| Middle East | 1 | 2020 | 1418 | 0.14 | Why? |
| Young Adult | 17 | 2019 | 93724 | 0.14 | Why? |
| Hypothyroidism | 1 | 2017 | 239 | 0.14 | Why? |
| HIV Infections | 2 | 2018 | 11620 | 0.14 | Why? |
| Ubiquitin-Protein Ligases | 1 | 2017 | 249 | 0.14 | Why? |
| Renin-Angiotensin System | 2 | 2021 | 3661 | 0.14 | Why? |
| Pregnancy Complications, Infectious | 1 | 2021 | 11559 | 0.14 | Why? |
| Sodium | 1 | 2017 | 309 | 0.14 | Why? |
| Hearing Loss, Sensorineural | 1 | 2017 | 159 | 0.14 | Why? |
| Spondylitis, Ankylosing | 1 | 2017 | 231 | 0.14 | Why? |
| Models, Econometric | 1 | 2015 | 69 | 0.14 | Why? |
| Neovascularization, Pathologic | 1 | 2018 | 305 | 0.14 | Why? |
| Pancreatic Diseases | 1 | 2017 | 191 | 0.14 | Why? |
| Sequence Analysis, DNA | 3 | 2018 | 2830 | 0.14 | Why? |
| Databases, Genetic | 1 | 2021 | 1127 | 0.14 | Why? |
| Genetic Variation | 2 | 2020 | 3919 | 0.14 | Why? |
| Disease Susceptibility | 4 | 2021 | 4002 | 0.14 | Why? |
| Viral Vaccines | 3 | 2020 | 7560 | 0.14 | Why? |
| Exosomes | 1 | 2021 | 567 | 0.14 | Why? |
| Risk Factors | 7 | 2021 | 71621 | 0.14 | Why? |
| Lymphocyte Count | 4 | 2019 | 4758 | 0.14 | Why? |
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 1014 | 0.14 | Why? |
| Drug Resistance | 1 | 2017 | 395 | 0.14 | Why? |
| Point Mutation | 1 | 2017 | 481 | 0.13 | Why? |
| Hodgkin Disease | 1 | 2016 | 204 | 0.13 | Why? |
| Intensive Care Units, Pediatric | 1 | 2021 | 1098 | 0.13 | Why? |
| Magnetic Resonance Spectroscopy | 1 | 2019 | 881 | 0.13 | Why? |
| Immunization, Passive | 2 | 2020 | 10067 | 0.13 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.13 | Why? |
| Probability | 1 | 2018 | 923 | 0.13 | Why? |
| Poliomyelitis | 1 | 2018 | 263 | 0.13 | Why? |
| Allergens | 2 | 2017 | 728 | 0.13 | Why? |
| Immune System Diseases | 1 | 2018 | 410 | 0.13 | Why? |
| Mast Cells | 1 | 2017 | 370 | 0.13 | Why? |
| Copper | 1 | 2017 | 288 | 0.13 | Why? |
| Ligands | 1 | 2018 | 1300 | 0.13 | Why? |
| Europe | 2 | 2021 | 12702 | 0.13 | Why? |
| China | 4 | 2021 | 50654 | 0.13 | Why? |
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2018 | 581 | 0.13 | Why? |
| CD4 Lymphocyte Count | 1 | 2018 | 1517 | 0.13 | Why? |
| Severity of Illness Index | 6 | 2021 | 48226 | 0.13 | Why? |
| Virus Activation | 1 | 2018 | 480 | 0.13 | Why? |
| Antigens, CD | 1 | 2018 | 984 | 0.13 | Why? |
| Genome, Viral | 5 | 2021 | 13157 | 0.12 | Why? |
| Dipeptidyl Peptidase 4 | 1 | 2020 | 1061 | 0.12 | Why? |
| Health Personnel | 2 | 2020 | 29646 | 0.12 | Why? |
| Asia | 1 | 2020 | 2399 | 0.12 | Why? |
| Interferon-alpha | 1 | 2021 | 1442 | 0.12 | Why? |
| Up-Regulation | 1 | 2021 | 2249 | 0.12 | Why? |
| Mothers | 2 | 2021 | 1624 | 0.12 | Why? |
| B-Lymphocyte Subsets | 2 | 2018 | 372 | 0.12 | Why? |
| IgA Deficiency | 1 | 2012 | 36 | 0.12 | Why? |
| Gene Regulatory Networks | 1 | 2018 | 820 | 0.12 | Why? |
| Quality of Life | 3 | 2018 | 9820 | 0.12 | Why? |
| Epstein-Barr Virus Infections | 1 | 2016 | 366 | 0.12 | Why? |
| Aged | 9 | 2021 | 215776 | 0.12 | Why? |
| Interdisciplinary Communication | 1 | 2020 | 1425 | 0.12 | Why? |
| Protective Factors | 1 | 2018 | 1720 | 0.12 | Why? |
| Orthomyxoviridae | 1 | 2021 | 1168 | 0.12 | Why? |
| Receptors, Interleukin-6 | 1 | 2020 | 1383 | 0.12 | Why? |
| Transcription, Genetic | 1 | 2018 | 1326 | 0.12 | Why? |
| Neuroimaging | 1 | 2019 | 1106 | 0.12 | Why? |
| DNA Mutational Analysis | 5 | 2017 | 581 | 0.11 | Why? |
| Viral Matrix Proteins | 1 | 2020 | 1243 | 0.11 | Why? |
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2020 | 645 | 0.11 | Why? |
| Cognition | 1 | 2021 | 1394 | 0.11 | Why? |
| Awareness | 1 | 2017 | 529 | 0.11 | Why? |
| Cell Line, Tumor | 1 | 2020 | 3608 | 0.11 | Why? |
| Adipose Tissue | 1 | 2017 | 612 | 0.11 | Why? |
| Patient Readmission | 1 | 2021 | 1543 | 0.11 | Why? |
| Middle Aged | 15 | 2021 | 270681 | 0.11 | Why? |
| Intellectual Disability | 1 | 2017 | 391 | 0.11 | Why? |
| Drug Delivery Systems | 1 | 2021 | 1365 | 0.11 | Why? |
| Vinblastine | 1 | 2010 | 48 | 0.11 | Why? |
| Pedigree | 4 | 2018 | 502 | 0.11 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.11 | Why? |
| Nose | 1 | 2017 | 1093 | 0.11 | Why? |
| Phagocytes | 1 | 2011 | 180 | 0.11 | Why? |
| Monocytes | 2 | 2020 | 2978 | 0.11 | Why? |
| Vincristine | 1 | 2010 | 89 | 0.11 | Why? |
| Hospitals, Pediatric | 2 | 2018 | 1792 | 0.11 | Why? |
| Leukocyte Count | 1 | 2021 | 3178 | 0.11 | Why? |
| Sex Factors | 2 | 2019 | 11014 | 0.11 | Why? |
| Cytarabine | 1 | 2010 | 64 | 0.10 | Why? |
| Mercaptopurine | 1 | 2010 | 68 | 0.10 | Why? |
| Nutritional Status | 1 | 2021 | 1403 | 0.10 | Why? |
| Disease Outbreaks | 5 | 2021 | 27595 | 0.10 | Why? |
| Codon, Nonsense | 1 | 2009 | 66 | 0.10 | Why? |
| Headache | 1 | 2021 | 2257 | 0.10 | Why? |
| Motivation | 1 | 2021 | 1640 | 0.10 | Why? |
| Health Literacy | 1 | 2020 | 1078 | 0.10 | Why? |
| Killer Cells, Natural | 1 | 2020 | 2093 | 0.10 | Why? |
| CARD Signaling Adaptor Proteins | 1 | 2009 | 70 | 0.10 | Why? |
| Multiple Organ Failure | 1 | 2020 | 1724 | 0.10 | Why? |
| Proteins | 2 | 2008 | 921 | 0.10 | Why? |
| Rhinitis, Allergic | 1 | 2017 | 704 | 0.10 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.10 | Why? |
| Zoonoses | 2 | 2020 | 3034 | 0.10 | Why? |
| Anti-Retroviral Agents | 1 | 2018 | 1099 | 0.10 | Why? |
| Clinical Laboratory Techniques | 3 | 2021 | 23402 | 0.09 | Why? |
| Inflammation Mediators | 2 | 2018 | 2654 | 0.09 | Why? |
| Smartphone | 1 | 2020 | 1840 | 0.09 | Why? |
| Telemedicine | 1 | 2020 | 25032 | 0.09 | Why? |
| Chiroptera | 2 | 2021 | 3530 | 0.09 | Why? |
| Cyclophosphamide | 1 | 2010 | 387 | 0.09 | Why? |
| Pregnancy | 2 | 2021 | 23879 | 0.09 | Why? |
| Milk, Human | 1 | 2017 | 956 | 0.09 | Why? |
| Sweat | 1 | 2009 | 127 | 0.09 | Why? |
| Global Health | 3 | 2020 | 13911 | 0.09 | Why? |
| Flow Cytometry | 4 | 2018 | 2393 | 0.09 | Why? |
| Dendritic Cells | 1 | 2017 | 1330 | 0.09 | Why? |
| Laboratories | 1 | 2021 | 2858 | 0.09 | Why? |
| Republic of Korea | 1 | 2021 | 5858 | 0.09 | Why? |
| Hospitals, University | 2 | 2018 | 4173 | 0.09 | Why? |
| Myeloid Differentiation Factor 88 | 2 | 2018 | 109 | 0.09 | Why? |
| Epitopes | 1 | 2020 | 4113 | 0.09 | Why? |
| Pregnancy Outcome | 1 | 2021 | 3803 | 0.09 | Why? |
| Exons | 2 | 2018 | 158 | 0.09 | Why? |
| Comorbidity | 3 | 2020 | 34796 | 0.09 | Why? |
| Protein Domains | 4 | 2020 | 6563 | 0.08 | Why? |
| Hematologic Neoplasms | 1 | 2021 | 2105 | 0.08 | Why? |
| Chronic Disease | 2 | 2020 | 5139 | 0.08 | Why? |
| Dyspnea | 1 | 2020 | 3847 | 0.08 | Why? |
| Prednisolone | 1 | 2010 | 443 | 0.08 | Why? |
| SARS Virus | 2 | 2021 | 13021 | 0.08 | Why? |
| Immunocompromised Host | 2 | 2021 | 5150 | 0.08 | Why? |
| Cough | 1 | 2021 | 4891 | 0.08 | Why? |
| Prospective Studies | 4 | 2021 | 43301 | 0.08 | Why? |
| Health Promotion | 1 | 2020 | 2020 | 0.08 | Why? |
| Cyclosporine | 1 | 2010 | 449 | 0.08 | Why? |
| Methotrexate | 1 | 2010 | 471 | 0.08 | Why? |
| CD8-Positive T-Lymphocytes | 2 | 2021 | 5837 | 0.08 | Why? |
| Genomics | 1 | 2018 | 3118 | 0.08 | Why? |
| Software | 1 | 2018 | 2501 | 0.08 | Why? |
| Prednisone | 1 | 2010 | 652 | 0.08 | Why? |
| Whole Exome Sequencing | 2 | 2018 | 437 | 0.08 | Why? |
| RNA, Messenger | 4 | 2018 | 5131 | 0.07 | Why? |
| Mental Health | 3 | 2021 | 15770 | 0.07 | Why? |
| Diabetes Complications | 1 | 2018 | 2358 | 0.07 | Why? |
| Germany | 1 | 2021 | 9196 | 0.07 | Why? |
| Anti-HIV Agents | 1 | 2018 | 2209 | 0.07 | Why? |
| HEK293 Cells | 1 | 2018 | 8394 | 0.07 | Why? |
| Histocompatibility Antigens Class II | 1 | 2007 | 383 | 0.07 | Why? |
| Myocarditis | 1 | 2020 | 2731 | 0.07 | Why? |
| Anticonvulsants | 1 | 2010 | 634 | 0.07 | Why? |
| Public Health | 2 | 2021 | 16359 | 0.07 | Why? |
| Stress Disorders, Post-Traumatic | 1 | 2021 | 2963 | 0.07 | Why? |
| Delivery of Health Care | 2 | 2021 | 15909 | 0.07 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2021 | 3892 | 0.07 | Why? |
| France | 1 | 2021 | 12074 | 0.07 | Why? |
| Cost of Illness | 1 | 2015 | 1903 | 0.07 | Why? |
| Fever | 1 | 2021 | 7795 | 0.07 | Why? |
| Lung Neoplasms | 1 | 2021 | 3228 | 0.06 | Why? |
| Prevalence | 4 | 2021 | 25773 | 0.06 | Why? |
| Antigens, Viral | 1 | 2021 | 6298 | 0.06 | Why? |
| Tomography, X-Ray Computed | 2 | 2020 | 25144 | 0.06 | Why? |
| Host-Pathogen Interactions | 2 | 2020 | 11041 | 0.06 | Why? |
| Viral Nonstructural Proteins | 1 | 2021 | 4810 | 0.06 | Why? |
| Coronavirus | 3 | 2021 | 18339 | 0.06 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.06 | Why? |
| Antineoplastic Agents | 1 | 2019 | 3550 | 0.06 | Why? |
| Intracellular Signaling Peptides and Proteins | 2 | 2018 | 334 | 0.06 | Why? |
| Histocompatibility Antigens Class I | 1 | 2007 | 624 | 0.06 | Why? |
| Cell Line | 1 | 2018 | 12040 | 0.06 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 5277 | 0.06 | Why? |
| Prognosis | 3 | 2021 | 32490 | 0.06 | Why? |
| Magnetic Resonance Imaging | 1 | 2019 | 6551 | 0.06 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.06 | Why? |
| Travel | 1 | 2021 | 7220 | 0.06 | Why? |
| Neutrophils | 1 | 2018 | 5476 | 0.06 | Why? |
| Internet | 1 | 2020 | 6204 | 0.06 | Why? |
| Glucocorticoids | 1 | 2017 | 4431 | 0.05 | Why? |
| Real-Time Polymerase Chain Reaction | 2 | 2018 | 11367 | 0.05 | Why? |
| Social Isolation | 1 | 2021 | 5932 | 0.05 | Why? |
| Algorithms | 1 | 2018 | 7346 | 0.05 | Why? |
| Pan troglodytes | 1 | 2020 | 157 | 0.05 | Why? |
| Saliva | 1 | 2017 | 4679 | 0.05 | Why? |
| Brain | 1 | 2018 | 5133 | 0.05 | Why? |
| G2 Phase Cell Cycle Checkpoints | 1 | 2019 | 25 | 0.05 | Why? |
| Asia, Southeastern | 1 | 2021 | 390 | 0.05 | Why? |
| Sequence Homology | 1 | 2021 | 448 | 0.05 | Why? |
| Sensitivity and Specificity | 1 | 2021 | 22971 | 0.05 | Why? |
| Cells, Cultured | 3 | 2018 | 5835 | 0.05 | Why? |
| Immunophenotyping | 2 | 2018 | 1290 | 0.05 | Why? |
| Candida | 2 | 2017 | 425 | 0.05 | Why? |
| Multiplex Polymerase Chain Reaction | 2 | 2018 | 1439 | 0.05 | Why? |
| Mathematical Concepts | 1 | 2021 | 370 | 0.05 | Why? |
| Thrombosis | 1 | 2021 | 7504 | 0.05 | Why? |
| Disease Progression | 1 | 2018 | 13580 | 0.05 | Why? |
| Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2018 | 29 | 0.05 | Why? |
| Suppressor of Cytokine Signaling 1 Protein | 1 | 2018 | 28 | 0.05 | Why? |
| Recurrence | 2 | 2020 | 3675 | 0.05 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.05 | Why? |
| Caffeine | 1 | 2019 | 67 | 0.05 | Why? |
| Zinc Fingers | 1 | 2018 | 109 | 0.05 | Why? |
| Gene Duplication | 1 | 2017 | 31 | 0.04 | Why? |
| Mitogen-Activated Protein Kinase 14 | 1 | 2017 | 20 | 0.04 | Why? |
| Interleukin-1 Receptor-Associated Kinases | 1 | 2018 | 56 | 0.04 | Why? |
| Epilepsy | 1 | 2010 | 1401 | 0.04 | Why? |
| Neoplasm, Residual | 1 | 2018 | 147 | 0.04 | Why? |
| Immunoglobulin Isotypes | 1 | 2019 | 308 | 0.04 | Why? |
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2016 | 58 | 0.04 | Why? |
| Oligonucleotides | 1 | 2018 | 137 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.04 | Why? |
| Exome | 1 | 2018 | 207 | 0.04 | Why? |
| Poliovirus Vaccine, Oral | 1 | 2018 | 95 | 0.04 | Why? |
| Quality-Adjusted Life Years | 1 | 2019 | 511 | 0.04 | Why? |
| Selection, Genetic | 1 | 2020 | 691 | 0.04 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.04 | Why? |
| Base Sequence | 2 | 2017 | 3581 | 0.04 | Why? |
| Species Specificity | 1 | 2020 | 1356 | 0.04 | Why? |
| Tumor Burden | 1 | 2018 | 369 | 0.04 | Why? |
| Hospital Mortality | 1 | 2020 | 22087 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Cattle | 1 | 2020 | 1336 | 0.04 | Why? |
| Odds Ratio | 2 | 2018 | 5861 | 0.04 | Why? |
| Italy | 1 | 2021 | 38444 | 0.04 | Why? |
| Lymphoproliferative Disorders | 1 | 2017 | 110 | 0.04 | Why? |
| Loss of Function Mutation | 1 | 2018 | 244 | 0.04 | Why? |
| Islets of Langerhans | 1 | 2017 | 138 | 0.04 | Why? |
| Genetic Markers | 1 | 2017 | 318 | 0.04 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.04 | Why? |
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 3633 | 0.04 | Why? |
| Geography, Medical | 1 | 2018 | 537 | 0.04 | Why? |
| Cell Nucleus | 1 | 2018 | 399 | 0.04 | Why? |
| Global Burden of Disease | 1 | 2019 | 531 | 0.04 | Why? |
| Smokers | 1 | 2021 | 550 | 0.04 | Why? |
| Serogroup | 1 | 2018 | 510 | 0.04 | Why? |
| Gene Deletion | 1 | 2017 | 430 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.04 | Why? |
| Diabetes Mellitus, Experimental | 1 | 2017 | 192 | 0.04 | Why? |
| Cytotoxicity, Immunologic | 1 | 2016 | 287 | 0.04 | Why? |
| Follow-Up Studies | 3 | 2018 | 17020 | 0.04 | Why? |
| Th2 Cells | 1 | 2018 | 680 | 0.03 | Why? |
| Symptom Assessment | 2 | 2019 | 4967 | 0.03 | Why? |
| Troponin | 1 | 2020 | 1058 | 0.03 | Why? |
| Intestinal Diseases | 1 | 2017 | 231 | 0.03 | Why? |
| Transplantation, Homologous | 1 | 2017 | 757 | 0.03 | Why? |
| Computational Biology | 2 | 2021 | 4514 | 0.03 | Why? |
| Platelet Count | 1 | 2020 | 1381 | 0.03 | Why? |
| Cats | 1 | 2020 | 1890 | 0.03 | Why? |
| Open Reading Frames | 1 | 2021 | 1898 | 0.03 | Why? |
| Retrospective Studies | 3 | 2021 | 105322 | 0.03 | Why? |
| Recombination, Genetic | 1 | 2020 | 1265 | 0.03 | Why? |
| Plasma Cells | 1 | 2017 | 464 | 0.03 | Why? |
| United States | 1 | 2021 | 46150 | 0.03 | Why? |
| Herpesvirus 4, Human | 1 | 2016 | 387 | 0.03 | Why? |
| Natriuretic Peptide, Brain | 1 | 2020 | 1215 | 0.03 | Why? |
| Cross-Sectional Studies | 2 | 2021 | 53120 | 0.03 | Why? |
| Virus Attachment | 1 | 2020 | 1259 | 0.03 | Why? |
| Dogs | 1 | 2020 | 2529 | 0.03 | Why? |
| Registries | 3 | 2018 | 12327 | 0.03 | Why? |
| Incidence | 3 | 2021 | 25622 | 0.03 | Why? |
| Markov Chains | 1 | 2015 | 502 | 0.03 | Why? |
| Ultrasonography | 1 | 2009 | 4409 | 0.03 | Why? |
| Cost Savings | 1 | 2015 | 296 | 0.03 | Why? |
| Neoplasm Proteins | 1 | 2018 | 501 | 0.03 | Why? |
| Surveys and Questionnaires | 2 | 2017 | 43792 | 0.03 | Why? |
| Monte Carlo Method | 1 | 2015 | 577 | 0.03 | Why? |
| Interferon-beta | 1 | 2018 | 979 | 0.03 | Why? |
| Pneumococcal Vaccines | 1 | 2018 | 571 | 0.03 | Why? |
| Phylogeny | 2 | 2021 | 13341 | 0.03 | Why? |
| Viral Proteins | 2 | 2021 | 7370 | 0.03 | Why? |
| Cell Differentiation | 1 | 2018 | 1338 | 0.03 | Why? |
| Respiratory Mucosa | 1 | 2020 | 1522 | 0.03 | Why? |
| History, 20th Century | 1 | 2018 | 1282 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.03 | Why? |
| Atherosclerosis | 1 | 2019 | 768 | 0.03 | Why? |
| Lod Score | 1 | 2009 | 7 | 0.03 | Why? |
| Meningitis, Fungal | 1 | 2009 | 17 | 0.03 | Why? |
| Aged, 80 and over | 1 | 2021 | 88759 | 0.03 | Why? |
| NF-kappa B | 1 | 2017 | 1301 | 0.03 | Why? |
| Leukocytes | 1 | 2017 | 1046 | 0.03 | Why? |
| Epitopes, T-Lymphocyte | 1 | 2021 | 2262 | 0.02 | Why? |
| Amino Acid Sequence | 1 | 2021 | 6049 | 0.02 | Why? |
| Antigens, CD20 | 1 | 2009 | 105 | 0.02 | Why? |
| Disabled Persons | 1 | 2019 | 1152 | 0.02 | Why? |
| Brain Chemistry | 1 | 2008 | 49 | 0.02 | Why? |
| Neprilysin | 1 | 2009 | 112 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.02 | Why? |
| Lymphocyte Activation | 1 | 2018 | 2742 | 0.02 | Why? |
| Insulin | 1 | 2017 | 1316 | 0.02 | Why? |
| Binding Sites | 1 | 2020 | 6201 | 0.02 | Why? |
| Thrombocytopenia | 1 | 2021 | 2093 | 0.02 | Why? |
| BCG Vaccine | 1 | 2018 | 1137 | 0.02 | Why? |
| Genetics, Population | 1 | 2007 | 162 | 0.02 | Why? |
| Immunization | 1 | 2017 | 2019 | 0.02 | Why? |
| Evolution, Molecular | 1 | 2021 | 3691 | 0.02 | Why? |
| Membrane Potential, Mitochondrial | 1 | 2006 | 102 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2020 | 3129 | 0.02 | Why? |
| Protein Isoforms | 1 | 2008 | 347 | 0.02 | Why? |
| Mutant Proteins | 1 | 2008 | 328 | 0.02 | Why? |
| Clinical Decision-Making | 1 | 2020 | 3755 | 0.02 | Why? |
| Chromosome Mapping | 1 | 2006 | 178 | 0.02 | Why? |
| Health Care Costs | 1 | 2015 | 1007 | 0.02 | Why? |
| Breast Feeding | 1 | 2017 | 1585 | 0.02 | Why? |
| Oxidative Stress | 1 | 2017 | 2050 | 0.02 | Why? |
| Tissue Distribution | 1 | 2008 | 483 | 0.02 | Why? |
| Forecasting | 1 | 2021 | 4492 | 0.02 | Why? |
| Early Diagnosis | 1 | 2015 | 2443 | 0.02 | Why? |
| Patient Care | 1 | 2017 | 1664 | 0.02 | Why? |
| Databases, Factual | 1 | 2021 | 6248 | 0.02 | Why? |
| Candidiasis | 1 | 2009 | 334 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2018 | 6543 | 0.02 | Why? |
| T-Lymphocyte Subsets | 1 | 2012 | 1387 | 0.02 | Why? |
| Immunologic Memory | 1 | 2016 | 3362 | 0.02 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 2426 | 0.02 | Why? |
| Vaccination | 2 | 2021 | 19050 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.02 | Why? |
| Mortality | 1 | 2020 | 7132 | 0.02 | Why? |
| Models, Statistical | 1 | 2021 | 5312 | 0.02 | Why? |
| Time Factors | 2 | 2021 | 31397 | 0.02 | Why? |
| Survival Rate | 1 | 2017 | 9206 | 0.02 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2018 | 4545 | 0.02 | Why? |
| Disease Management | 1 | 2020 | 6841 | 0.01 | Why? |
| Molecular Diagnostic Techniques | 1 | 2018 | 4239 | 0.01 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 7868 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.01 | Why? |
| Syndrome | 1 | 2006 | 1310 | 0.01 | Why? |
| Myeloid Cells | 1 | 2006 | 808 | 0.01 | Why? |
| Population Surveillance | 1 | 2018 | 4967 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2017 | 8495 | 0.01 | Why? |
| Air Pollutants | 1 | 2017 | 3110 | 0.01 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2019 | 6166 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2018 | 13720 | 0.01 | Why? |
| Cohort Studies | 1 | 2021 | 36005 | 0.01 | Why? |
| Respiratory Tract Infections | 1 | 2017 | 6817 | 0.01 | Why? |
| Depression | 1 | 2017 | 14116 | 0.01 | Why? |
| Anxiety | 1 | 2017 | 17311 | 0.01 | Why? |